Vimarsana
Biggest News Aggregation in the World

Page 38 - Impact Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Impact Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Impact Foundation Today - Breaking & Trending Today

How to Succeed in Turbulent Times - Vimarsana News

How to Succeed in Turbulent Times

/PRNewswire/ -- A new Community Forum webinar series from the Auerbach Global-Impact Foundation (www.theAGIF.org) designed to empower nonprofits' success will...

Sudheer Sandra, Psychologist, founder of SUPAR school - World's First Digital Parallel School, enters the International Wonder Book of Records - Vimarsana News

Sudheer Sandra, Psychologist, founder of SUPAR school - World's First Digital Parallel School, enters the International Wonder Book of Records

Hyderabad (Telangana) [India], May 11 (ANI/PNN): Sudheer Sandra, Founder & Managing Director of the world's first parallel digital school 'SUPAR School' has found a coveted place in the International Wonder Book of Record for his unique feat of training about 15,480 students from 153 schools in just 24 days.

Nature's Sunshine Products' (NATR) CEO Terrence Moorehead on Q1 2022 Results - Earnings Call Transcript - Vimarsana News

Nature's Sunshine Products' (NATR) CEO Terrence Moorehead on Q1 2022 Results - Earnings Call Transcript

Nature’s Sunshine Products, Inc. (NASDAQ:NASDAQ:NATR) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Nathan Brower – Executive Vice President and General...

Natures Sunshine Products (NATR) Q1 2022 Earnings Call Transcript - Vimarsana News

Natures Sunshine Products (NATR) Q1 2022 Earnings Call Transcript

NATR earnings call for the period ending March 31, 2022.

Source: fool.com
Sanofi Strikes Deal With Mysterious Psychedelics Biotech Terran - Vimarsana News

Sanofi Strikes Deal With Mysterious Psychedelics Biotech Terran

New York-based Terran Biosciences inked a deal with Paris-based Sanofi for two late-stage central nervous system (CNS) assets. Terran plans to advance them for neurological and psychological indications.